Climb Bio Inc
CLYM5.440USD
+0.790+16.99%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
370.92MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Climb Bio Inc Unternehmen
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Climb Bio Inc Informationen
BörsenkürzelCLYM
Name des UnternehmensClimb Bio Inc
IPO-datumAug 10, 2021
CEOBrennan (Aoife M)
Anzahl der mitarbeiter17
WertpapierartOrdinary Share
GeschäftsjahresendeAug 10
Addresse20 William Street
StadtWELLESLEY HILLS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02481
Telefon18668572596
Websitehttps://climbbio.com/
BörsenkürzelCLYM
IPO-datumAug 10, 2021
CEOBrennan (Aoife M)
Führungskräfte von Climb Bio Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
+48132.00%
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Susan Altschuller, Ph.D.
Dr. Susan Altschuller, Ph.D.
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
+48132.00%
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
16.57%
Pontifax Venture Capital
7.64%
The Vanguard Group, Inc.
1.97%
Affinity Asset Advisors LLC
1.91%
Kynam Capital Management LP
1.51%
Andere
70.41%
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
16.57%
Pontifax Venture Capital
7.64%
The Vanguard Group, Inc.
1.97%
Affinity Asset Advisors LLC
1.91%
Kynam Capital Management LP
1.51%
Andere
70.41%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
24.25%
Hedge Fund
9.63%
Investment Advisor
7.53%
Investment Advisor/Hedge Fund
1.15%
Individual Investor
0.81%
Research Firm
0.80%
Andere
55.83%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
180
50.12M
94.21%
+7.08K
2025Q3
182
50.11M
95.00%
-5.30M
2025Q2
174
55.41M
95.70%
-2.05M
2025Q1
161
57.46M
90.60%
-8.97M
2024Q4
149
56.10M
86.82%
+979.54K
2024Q3
120
56.83M
81.50%
+4.66M
2024Q2
84
51.93M
31.41%
+31.40M
2024Q1
82
18.86M
80.37%
-3.42M
2023Q4
86
18.86M
80.98%
+125.11K
2023Q3
87
18.73M
82.50%
-1.84K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
17.90M
26.26%
-13.52M
-43.02%
Dec 12, 2025
Pontifax Venture Capital
5.21M
7.64%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.32M
1.93%
-15.44K
-1.16%
Sep 30, 2025
Affinity Asset Advisors LLC
1.30M
1.91%
-200.00K
-13.33%
Sep 30, 2025
Kynam Capital Management LP
1.03M
1.51%
--
--
Sep 30, 2025
Tang Capital Management, LLC
1.00M
1.47%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
694.98K
1.02%
-134.65K
-16.23%
Sep 30, 2025
Peapod Lane Capital LLC
561.87K
0.82%
+6.20K
+1.12%
Sep 30, 2025
Cantor Fitzgerald, L.P
547.17K
0.8%
-1.96M
-78.14%
Sep 30, 2025
Renaissance Technologies LLC
537.10K
0.79%
+41.60K
+8.40%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Russell 2000 Value ETF
0%
Mehr Anzeigen
ProShares Ultra Nasdaq Biotechnology
Anteil0.01%
iShares Biotechnology ETF
Anteil0.01%
Invesco Nasdaq Biotechnology ETF
Anteil0.01%
iShares Micro-Cap ETF
Anteil0.01%
Avantis US Small Cap Equity ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
iShares Neuroscience and Healthcare ETF
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
